Receives Patents for Real-Time Single-Molecule DNA Sequencing
on: February 17, 2008, 6:28 pm
Release Author: Susan Hardin
Release Summary: VisiGen Biotechnologies, Inc., was awarded US Patent
No. 7,329,492, "Methods for Real-time Single Molecule Sequence
Determination", in addition to European and Australian counterparts.
Release Body: HOUSTON, TX – February 15, 2008 - VisiGen
Biotechnologies, Inc., was awarded US Patent No. 7,329,492,
"Methods for Real-time Single Molecule Sequence Determination",
European and Australian counterparts have also recently issued.
VisiGen's President, Dr. Susan Hardin, Ph.D. said, "We
have the real path to the $1,000 human genome." VisiGen's
sequencing methodology can be used to sequence the genome of a human
or any other life form.
DNA sequencing machines will enable low cost comprehensive
genome analysis such as a one day, $1,000 human genome. VisiGen's
patented technology is scalable. VisiGen's nanosequencing
machines are designed to monitor massively parallel arrays
to produce a DNA sequencing platform that will
be capable of collecting DNA sequence data at the
rate of 50 million bases per second or greater. VisiGen plans to
offer a DNA sequencing service in late 2009 and to sell DNA
sequencing machines and reagents 18 to 24 months later.
has bioengineered polymerases and nucleotides to act together
as direct molecular sensors of DNA sequence information
during DNA replication. VisiGen's
novel platform uses single-molecule DNA detection,
fluorescent molecule chemistry, computational biochemistry, and
biomolecule engineering and purification. VisiGen's
method tags the terminal phosphate of a nucleotide with a fluorophore
that is naturally released during nucleotide insertion into the
growing DNA strand, thereby enabling a non-cyclical
approach to DNA sequencing.
believe that our newly issued patent pre-dates certain other sequencing
methodologies based on the use of terminal phosphate labeled nucleotides,"
Dr. Hardin said, "so not only do we have to be mindful
of the medical and pharmaceutical implications of our technology,
but we must also be mindful of our own patent position in this fast
VisiGen is a privately owned company located in
Houston, Texas. VisiGen was founded in 2000 by
the inventors of this revolutionary technology: Drs. Susan
Hardin, Xiaolian Gao, Jim Briggs, Richard Willson, and Shiao-Chun
(David) Tu. VisiGen is a spin-off from the University
company has received undisclosed investments from Applied
Biosystems and SeqWright, and also is supported by grants
from the Defense Advanced Research Projects Agency,
the National Human Genome Research Institute, and
the National Institute of General Medical Sciences.
is a contender for the Archon X-Prize for Genomics,
which will award a $10 million prize to the first entrant to sequence
100 human genomes in 10 days for no more than $10,000 per genome.
Details: Susan Hardin, Ph. D.
2575 West Bellfort, Suite 250
to previous page...
to home page...
your press releases...